NCT00772863View on ClinicalTrials.gov

Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

June 30, 2008

Conditions

Ovarian Neoplasms

Interventions

DRUG

docetaxel and cisplatin

4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks

Trial Locations (1)

Unknown

Sanofi aventis administrative office, Istanbul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY